Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 7;6:e2200040. doi: 10.1200/PO.22.00040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 3. — Response to combined treatment with osimertinib and pralsetinib. Before treatment: (A) lung tumor in left upper lobe (5.1 cm; arrow), (B) liver metastasis (1.7 cm; arrow), and (C) residual liver metastasis (nonmeasurable; arrow). First assessment: (D) lung tumor in left upper lobe (4.3 cm; arrow), (E) liver metastasis (1.1 cm; arrow), and (F) residual liver metastasis (4.6 cm; arrow). Second assessment: (G) lung tumor in left upper lobe (4.0 cm; arrow), (H) liver metastasis (nonmeasurable; arrow), and (I) residual liver metastasis (3.8 cm; arrow). Third assessment: (J) lung tumor in left upper lobe (3.9 cm; arrow), (K) liver metastasis (nonvisible), and (L) residual liver metastasis (3.8 cm; arrow).